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ABSTRACT 
Propofol is an intravenous sedative-hypnotic agent indicated for induction and maintenance of 
general anesthesia as well as for sedation of intubated, mechanically ventilated adults in intensive 
care units (ICU). Propofol is characterized by a phenolic structure similar to that of α-tocopherol, 
and presents antioxidant properties that have been demonstrated both in vitro and in vivo. The aim 
of the present review is to evaluate the antioxidant properties of propofol in various models and 
whether or not it may be considered an efficient therapeutic tool in counteracting oxidative stress 
during general anesthesia and sedation in ICU.  
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Oxidative stress occurs when there is an 
imbalance between generation of reactive 
oxygen species (ROS) and inadequate 
antioxidant defence systems leading to cell 
damage either directly or through altering 
signalling pathways. The consequence of 
oxidative stress may be oxidative damage of 
lipids, proteins, and DNA, with subsequent 
disease development and aging (Finkel et al., 
2000). ROS production may result from 
exogenous factors such as radiation and drug 
exposure or endogenous factors such as 
increased mitochondrial respiration and 
oxidative enzymes in infections and 
inflammation. Of particular interest to the 
researchers such as anesthetists, intensive care 
physicians and surgeons are free radical 
mediated reperfusion injuries such it occurs 
following organ transplantation, and free radical 
and endotoxin induced acute inflammatory 
processes such as lung injury, severe sepsis, 
multi-system organ failure. Free radical 
scavengers, or anti-oxidants, represent an 
important component of the body’s defence 
against oxygen-centered free radical mediated 
injuries, so that boosting of these defences by 
pharmacological means may emerge as an 
important therapeutic goal. The roles of 
vitamins A and E, ascorbic acid, salicylates, 
barbiturates, superoxide dismutase, 
polyunsaturated fatty acids and anti-
inflammatory agents in ameliorating free radical 
damage are just but few examples of the 
importance of antioxidants in protecting tissues 
against oxidative stress (Aruoma et al., 1991; 
Buettner 1993; Przyklenk et al., 1989). 
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The aim of the present review is to evaluate the 
antioxidant properties of propofol in both in 
vivo and in vitro models and whether or not it 
may be considered an efficient therapeutic tool 
in counteracting oxidative stress during general 
anesthesia and sedation in the intensive care 
units (ICU). 
 
 
 
Propofol is an intravenous sedative-hypnotic 
agent commercially introduced in the United 
States in 1989 by Zeneca Pharmaceuticals. It 
was the first of a new class of intravenous 
anesthetic agents: the alkylphenols.  It is 
indicated for induction and maintenance of 
general anesthesia as well as for sedation of 
intubated, mechanically ventilated adults in 
ICU. Propofol is characterized by a phenolic 
structure similar to that of α-tocopherol (Figure 
1), and presents antioxidant properties that have 
been demonstrated both in vitro and in vivo.  
 
 Many polyphenols have antioxidant 
properties (i.e., reductants) and may react 
directly with reactive chemical species, forming 
products with much lower reactivity. 
 
In 1989, Weir D. et al (Weir et al., 1989) 
observed for the first time that propofol 
attenuated experimental reperfusion injury in 
the cerebral cortex thus pointing out the 
antioxidant properties of this compound. 
Furthermore, Murphy PG et al (Murphy et al., 
1992) demonstrated that propofol reacts with 
peroxynitrite leading to the formation of a more 
stable propofol-derived phenoxyl radical and 
has therefore been hypothesized to be a 
peroxynitrite scavenger. As concern propofol 
scavenging activity, Green TR et al. (Green et 
al., 1994) evaluated the specificity of propofol 
as a scavenger of oxygen and organic radical 
species showing that propofol prefentially 
scavenges organoradical species since it was 
able to reduce significantly riboflavin radicals 
and the formation of malondialdehyde 
degradation products
 
Figure 1: Chemical structure of α-tocopherol 
(A) and propofol (B) showing their polyphenolic 
nature. 
 
 
generated from lipid hydroperoxides of 
arachidonic acid. These results were further 
confirmed by following studies showing that 
propofol is able to inhibit lipid peroxidation in 
various experimental models (Sayin et al., 2002; 
Manataki et al., 2001) to protect cells against 
oxidative stress and to increase the anti-oxidant 
capacity of plasma in humans (Stratford et al., 
1998; Chen et al., 2005; Hans et al., 1997; 
Sagara et al., 1999). Alternatively, polyphenols 
may increase the capacity of endogenous 
antioxidant defences and modulate the cellular 
redox state. Changes in the cellular redox state, 
conveying physiologic stimuli through 
regulation of signalling pathways, may have 
wide-ranging consequences for cellular growth 
and differentiation. In addition, it has been well 
documented that polyphenols  modulate protein 
kinase activities (Agarwal 2000), serve as 
ligands for transcription factors  (Amakura et 
al., 2003), and modulate protease activities 
(Moon et al., 2003).  The majority of in vitro 
and in vivo studies conducted so far have 
attributed the protective effect of bioactive 
polyphenols to their chemical reactivity toward 
free radicals and their capacity to prevent the 
oxidation of important 
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Figure 2: Schematic representation of HO activity. 
intracellular components. However, Scapagnini 
G et al. (Scapagnini et al., 2002) suggested a 
possible novel aspect in the mode of action of 
these compounds; that is, the ultimate 
stimulation of the heme oxygenase-1 (HO-1) 
pathway is likely to account for the established 
and powerful antioxidant/anti-inflammatory 
properties of these polyphenols. In 2004, we 
studied experimentally and proved scavenger 
activity and effects on the HO system as an 
alternative and additional protective mechanism 
of propofol (Acquaviva et al., 2004). HO 
isoforms catalyze the conversion of heme to 
carbon monoxide (CO) and biliverdin/bilirubin 
with a concurrent release of iron, which can 
drive the synthesis of ferritin for iron 
sequestration (Eisenstein et al., 1991; Shibahara 
et al., 1993) (Figure 2). 
 
HO is the limiting step in heme degradation and, 
consequently, plays a critical role in regulating 
the levels of cellular heme available for 
structural and functional heme- 
 
 
 
 
 
dependent proteins (Abraham et al., 1988). To 
date, two HO isoforms have been shown to be 
catalytically active in heme degradation, and 
each is encoded by a different gene 
(McCoubrey, Jr. et al., 1992; Shibahara et al., 
1993). HO-1, the inducible isoform, is found 
ubiquitously in all organs with the exception of 
the adult brain and is rapidly and transiently 
expressed by a range of stressful stimuli; in 
contrast, HO-2 is the constitutive isozyme 
which, apart from controlling the basal levels of 
heme in the majority of cells, may also mediate 
important physiological effects such as 
vasodilatation and neurotransmission (Abraham 
et al., 1988).  We demonstrated that 
peroxynitrite cytotoxicity in astrocytes is 
significantly attenuated by propofol in a dose-
dependent manner. Furthermore, we showed 
that peroxynitrite-mediated DNA damage was 
attenuated by the addition of propofol in a dose-
dependent manner. In this study, all the
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above mentioned antioxidant effects of propofol 
were mitigated by the addition of SnMP, a 
strong pharmacological inhibitor of HO activity, 
thus suggesting HO as a protective pathway of 
propofol (Figure 3).  
 
Our results are consistent with previous clinical 
studies supporting also a protective effect of 
propofol against peroxidative injury. Propofol 
reduced levels of malondialdehyde, a marker of 
lipid peroxidation, after tourniquet-induced 
lower limb ischemia-reperfusion injury 
(Aldemir et al., 2001), and decreased oxidative 
damage measured in platelets (De La Cruz et 
al., 1999) from surgical patients. These in vivo 
results were further confirmed by Sayin MM 
and Zhang SH et al. (Sayin et al., 2002; Zhang 
et al., 2004), demonstrating that during coronary 
artery bypass grafting operations, propofol was 
more efficient than fentanyl in suppressing lipid 
peroxidation, F2-isoprostanes, complement C5a 
and neutrophil adhesion rate. 
 
In addition, propofol mediated HO-1 induction 
may explain in part some effects of this 
compound on important hemeproteins such as 
cytochrome P450 (CYP450) and 
cyclooxygenase. In this regard, Yang LQ et al. 
(Yang et al., 2003) showed that propofol may be 
a potential CYP450 inhibitor as it can 
significantly inhibit 3A4 isoenzyme activity 
without significantly affecting the protein 
expression. Furthermore, Ogawa K. et al. 
(Ogawa et al., 2001) showed that propofol 
reduces cyclooxygenase activity, as measured 
by prostaglandin production. Recently, Li Volti 
G. et al. (Li Volti et al., 2003) showed that 
pharmacological and retroviral mediated 
upregulation of HO-1 reduces intracellular heme 
content and this may account for reduced 
cyclooxygenase activity. Consistently with our 
observations, Taille C et al (Taille et al., 2004) 
elegantly demonstrated that a decrease in heme 
content due to HO-1 activation limits heme 
availability for maturation of the gp91(phox) 
subunit and
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Comet assay of genomic DNA of 
rat astrocytes. Astrocytes were treated for 
24 h with propofol and SIN-1, a 
peroxynitrite donor. Arrows indicate DNA 
fragmentation. 
 
assembly of the functional NAD(P)H oxidase 
and thus attenuating free radicals formation and 
oxidative stress damage. Since heme functions 
as the prosthetic group in both CYP3A4 and 
cyclooxygenase, propofol mediated HO-1 
induction may be responsible for their reduced 
activity by lowering intracellular heme content. 
In addition, since the gene encoding for HO-1 
protein contains an NFkB binding site which 
can be selectively recognized by the ubiquitous 
transcriptional factor NFkB (Lavrovsky et al., 
1993), we tested whether this important 
transcription factor could play a role in our 
experimental conditions. We showed that the 
addition of a synthetic NFkB inhibitor 
completely reversed propofol mediated HO-1 
expression thus suggesting that this nuclear 
factor is involved in the intracellular cascade 
following propofol treatment (Acquaviva et al., 
2004). 
 
Another important effect of propofol
 28
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
which needs also to be described for its clinical 
relevance is the antiapoptotic effect of this 
compound.
 
Apoptosis refers to programmed cell death. This 
endogenous program is essential in the 
modeling of organs during fetal life, enabling 
self-renewing processes, and eliminating 
infected or injured cells in adults. Superfluous 
cells die by apoptosis, and their death is initiated 
by a genetic program. When these dying cells 
have disintegrated into
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Signaling pathways of ischemia-induced apoptosis, including intrinsic (mitochondria-
mediated), extrinsic (receptor-mediated), and caspase-independent pathways. Apoptotic insults lead 
to cytochrome c release from the mitochondria into the cytoplasm, which forms the apoptosome 
consisting of Apaf-1 and procaspase 9 and then activate caspase 9. This ultimately results in 
activation of caspase 3. The release of cytochrome c is regulated by proapoptotic proteins Bax and 
antiapoptotic proteins Bcl-2 and Bcl-XL.The death receptor pathway is triggered by the binding of 
Fas ligand (FasL) to Fas, which activates caspase 8 via Fas-associated death domain protein 
(FADD). A number of different cell receptors and their ligands can be involved in this process. 
Activated caspase 8 then activates caspase 3 and can also interact with the intrinsic pathway by 
activating proapoptotic protein Bid. A caspase-independent pathway also exists in which apoptotic-
inducing factor is released from the mitochondria and directly causes chromatin condensation and 
DNA cleavage. 
 
apoptotic bodies, they are phagocytosed by 
macrophages without inflammatory response. 
Although the mechanism by which apoptosis is 
triggered is not clear, signaling pathways of 
ischemia-induced apoptosis may include 
intrinsic (mitochondria-mediated), extrinsic 
(receptor-mediated), and caspase-independent 
pathways  (Zheng et al., 2003).  The intrinsic 
pathway is characterized by cytochrome c 
release from mitochondria, which leads to 
procaspase 9 cleavage and 
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activation. This ultimately results in activation 
of effector  caspases, including caspase 3 
(Fujimura et al., 1998; Fujimura et al., 1999; 
Green 1998). The extrinsic pathway is 
characterized by activation of cell death 
receptors initiated by their ligands [e.g., FasL, 
tumor necrosis factor-α (TNF-α)], which leads 
to cleavage of procaspase 8. Cleaved caspase 8 
then activates downstream caspases and results 
in apoptosis (Martin-Villalba et al., 1999; 
Rosenbaum et al., 2000). By contrast,  
apoptosis-inducing factor (AIF), which is 
released from the mitochondria, is also thought 
to be an important candidate responsible for 
apoptosis via caspase-independent pathways 
(Zheng et al., 2003) (Figure 4). 
 
Engelhard K et al (Engelhard et al., 2004) 
showed that propofol possess antiapoptotic 
qualities by influencing apoptosis-regulating 
proteins after cerebral ischemia.  The  authors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
showed that expression of the pro-apoptotic 
protein Bax was greater in control animals than 
in propofol anaesthetized rats and than in sham-
operated animals. Consistently with these 
results, we showed that propofol treatment  was 
able to attenuate peroxynitrite mediated caspase 
3 activation probably via the generation of HO 
byproduct CO and/or bilirubin. 
 
However, whether the cytoprotective effect of 
propofol accurately translates to a therapeutic 
effect in patients remains uncertain.  
 
In conclusion, the data presented above show 
that propofol posses anti-oxidative and anti-
apoptotic properties, and involve important 
enzymatic systems, such as HO-1, in exerting its 
effects thus providing an important and 
powerful strategy for protection during 
anesthesia (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5: Schematic representation of possible protective mechanism(s) of propofol. 
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